Last reviewed · How we verify

Energique, Inc. — Portfolio Competitive Intelligence Brief

Energique, Inc. pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Dentastat PLATINUM marketed Non-Standardized Food Allergenic Extract [EPC] Immunology
Multi-Phenolic PIPERINE marketed Vitamin C [EPC] Metabolic
Multi-Phenolic PYRROLE marketed Vitamin C [EPC] Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 2 shared drug classes
  2. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
  3. Glaukos · 1 shared drug class
  4. Exela Pharma · 1 shared drug class
  5. Faculdade de Medicina do ABC · 1 shared drug class
  6. Forces of Nature · 1 shared drug class
  7. Chi Mei Medical Hospital · 1 shared drug class
  8. ABBVIE · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Energique, Inc.:

Cite this brief

Drug Landscape (2026). Energique, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/energique-inc. Accessed 2026-05-16.

Related